Follow the HLB생명과학 share price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, HLB생명과학 has logged 14 reports. Market capitalisation: €261.5bn. The latest transaction was filed on 1 July 2026 (Other). Among the most active insiders: HLB. Every trade is openly available.
14
Insider Decl.
n/a
Thresholds
n/a
2 ops.
Buy Volume
n/a
n/a
Sell Volume
5Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,338 of 29,062 companies
17.1
score / 100
Value
19
Quality
16
FCF yld-7.1%
Earn yld-7.6%
EV/EBITDA·
ROE-14%
Gross mgn13%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
HLB Life Science es una empresa especializada en el sector de la salud y farmacéutico, que cotiza en la bolsa XKRX. Se enfoca en el desarrollo de soluciones innovadoras para el tratamiento de enfermedades.